Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Positive preliminary SVR data were also presented.
  • AASLD 2010, IL28B Poster data showed that the addition of ANA598 to SOC has the potential to confer beneficial effect on HCV patients regardless of IL-28B genotype.
  • EASL 2010 and ICAR 2010, Preclinical Posters – presented data showing enhanced antiviral activity and suppression of resistance when ANA598 is combined in vitro with other anti-HCV agents that act through diverse mechanisms, including protease inhibition, polymerase inhibition (both nucleoside and non-nucleoside inhibitors) and cyclophilin inhibition (a host target).

  • Conference Call WebcastAnadys will host a conference call at 5:00 pm Eastern Standard Time today to discuss its fourth quarter and year-end 2010 financial results and highlights.  A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 62030425.  The webcast and telephone replay will be available through March 17, 2011.Condensed Consolidated Financial StatementsAnadys Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands except per share amounts)(Unaudited)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2010200920102009Operating expensesResearch and development

    $

    2,753$

    3,948$

    12,026$

    19,494General and administrative1,7271,6326,4788,243Total operating expenses (1)4,4805,58018,50427,737Interest income and other, net2544139610Gain (loss) from valuation of common sto
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
    (Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
    (Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
    (Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
    Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
    ... Two physicists from The University of Manchester who discovered ... for their work. , Professor Andre Geim FRS and ... Nanotechnology have been awarded the prestigious Europhysics Prize for ... reveal its remarkable electronic properties. , Graphene is a ...
    ... Inc.,(Nasdaq: MEDX ) announced today that it is ... at 9:10 a.m. Eastern Time on,Thursday, September 4, 2008. ... in the Investor Relations section of the Medarex website ... will be available,following the event., About Medarex, ...
    ... presentations included Resverlogix data, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... pertaining to its lead compound,RVX-208, at the European ... titled "RVX-208 a novel small molecule that increases,apolipoprotein ...
    Cached Biology Technology:Graphene pioneers follow in Nobel footsteps 2Medarex to Present at the Thomas Weisel Partners Healthcare Conference 2ApoA-I Data Presented at European Society of Cardiology Congress 2
    (Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
    (Date:8/21/2014)... that has implications for life in other extreme environments, ... system, LSU Associate Professor of Biological Sciences Brent Christner ... or NSF, this week published a paper confirming that ... 800 meters (2600 feet) beneath the surface of the ... that more than 400 subglacial lakes and numerous rivers ...
    (Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
    Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4New feeding tube connectors will improve patient safety 2
    ... cities is often an overlooked resource. Years of manufacturing or ... scare residents away from using the land. As the local ... desire to grow food in cities with the fear that ... 10:35 am, Kristen McIvor of the Pierce Conservation District will ...
    ... STATION Dr. Xiuren Zhang, a biochemist and ... has been awarded almost $1.3 million from the National ... and plant stem cells, which ultimately could help breed ... science foundation,s CAREER program, which is given in "support ...
    ... Microbial fuel cells, chemical sensors for your iPhone, ... faster-charging batteries, safer nuclear power, and new crime scene ... on the science of materials, interfaces, and processing. Detailed ... AVS 60th International Symposium & Exhibition will take place ...
    Cached Biology News:Fostering community gardens in an area with historic soil contamination 2AgriLife researcher Xiuren Zhang receives National Science Foundation CAREER grant 2AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2
    Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
    Pronase Reagent...
    Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
    p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
    Biology Products: